+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of adding a single-dose male HPV vaccination to the existing national HPV vaccination program for girls in northern Tanzania. This phase 4 cluster-randomized trial compares communities offering only the national program for girls aged about 14 years with those that also provide a single dose of the 4-valent HPV vaccine Gardasil to boys aged 14 to 18 years. The goal is to assess population genital HPV prevalence three years after vaccination in both males and females aged 18 to 21 years. In the intervention communities, boys aged 14 to 18 years receive one dose of Gardasil, which protects against HPV types 6, 11, 16, and 18. Girls aged 14 years in all communities receive two doses of Gardasil through the national vaccination program. Blood samples for immune response and safety monitoring are collected from a subset of 200 male participants in selected intervention clusters. The study is randomized with two parallel arms conducted across 26 communities. Participants are monitored for HPV prevalence at 36 months post-vaccination. The study also evaluates immunogenicity and safety at 12, 24, and 36 months, vaccine uptake and coverage, acceptability of a gender-neutral vaccination approach, and cost-effectiveness outcomes. Safety data and immune responses are collected through blood sampling in a subset of boys. The total study duration extends from August 2022 through December 2026.

Age: 14Years - 18YearsMALEPhase 4
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are estimating the prevalence of high-risk human papillomavirus HR HPV infections among girls and women aged 9 to 50 years across eight countries in South Asia and sub-Saharan Africa. This study aims to understand HPV infection rates in low socio-economic populations and specific sub-groups, including sexually active young women, by conducting cross-sectional surveys and longitudinal studies. Additionally, qualitative sub-studies will explore how gender norms and stigma affect HPV burden and access to prevention and treatment services. The study uses a harmonized protocol across all participating countries with country-specific adaptations. Cross-sectional surveys will collect urine samples from girls and women in urban and rural areas to estimate HPV prevalence. Longitudinal studies will follow sexually active girls and women aged 15 to 35 years over 24 months, collecting vaginal swabs and urine samples to measure persistent HPV infection. Qualitative studies will include interviews and focus groups to understand social factors influencing HPV risks and healthcare access. Participants will provide samples and answer standardized questionnaires on demographics, sexual and reproductive history, HPV vaccination, cervical cancer screening, and related attitudes. Testing will occur at enrollment and every six months for two years in longitudinal studies. Researchers will monitor HPV infection rates, assess questionnaire responses, and analyze laboratory results. The study includes safety follow-up and detailed data collection to provide comprehensive insight into HPV prevalence, incidence, and social influences in these populations.

Age: 9Years - 50YearsFEMALE
8 locations
E

Actively Recruiting

Researchers are evaluating new treatment regimens for pulmonary tuberculosis TB that aim to be faster while maintaining safety and effectiveness. This trial is conducted by the UNITE4TB consortium, a collaboration of universities and pharmaceutical companies, funded by the European Union. The study focuses on adults with newly diagnosed rifampicin-susceptible pulmonary TB and includes both drug-susceptible and potentially drug-resistant cases to find improved therapies. The trial has two main parts. In Phase 2B, up to 700 participants will be randomly assigned to one of several treatment groups, including a standard 24-week regimen and up to 16-week novel regimens combining new drugs like BTZ-043 and GSK3036656 with existing TB medications. Phase 2C will involve up to 1800 participants receiving selected regimens from Phase 2B for varying durations between 8 and 16 weeks. The study drugs are given orally with specific doses, and treatment combinations may change during the trial. Participants will be followed for a total of 72 weeks to monitor treatment response and safety. Assessments include measuring the time to positivity of sputum cultures, adverse events, and treatment outcomes such as relapse or failure. Safety monitoring covers serious and special interest adverse events. The trial includes regular visits and laboratory tests to evaluate the effectiveness and tolerability of the treatments over the duration of the study.

Age: 18Years +All GendersPhase 2
11 locations
L

Actively Recruiting

Researchers are conducting a long-term observational study called the SAFE study to follow people with sickle cell anemia SCA over time. The main goal is to understand how the medicine hydroxyurea affects growth, puberty, and fertility in adolescents and young adults with SCA. The study also compares pregnancy outcomes between those who take hydroxyurea and those who do not. Participants with SCA will be monitored regularly with clinic visits every few months for health check-ups and blood tests. Girls who have started menstruating will have pregnancy tests every six months, and boys may be asked to provide semen samples if they agree. The study will collect information on growth, development, fertility, and reproductive outcomes while observing how hydroxyurea impacts these aspects. During the study, participants will answer questions about their health and fertility at regular intervals. Researchers will track clinical outcomes and reproductive potential for up to 10 years after enrollment. This long-term follow-up will help gather important information on how hydroxyurea influences health and reproductive outcomes in people living with SCA.

Age: 8Years +All Genders
3 locations
D

Actively Recruiting

This observational multi-country cohort study focuses on children aged 5 to 16 years admitted to hospitals in East Africa with proven or suspected sepsis. The research aims to develop and improve algorithms that can identify children at risk of death after hospital discharge, addressing a critical period where many children face post-discharge mortality. The study builds on previous work with the Smart Discharges program to better predict and support vulnerable children during this time. Participants are enrolled upon admission to pediatric wards, where clinical and social data are collected. The study includes three phases first, developing and validating a prediction model for post-discharge mortality using data from 4,000 children second, evaluating health-related quality of life and functional status in a subset of 500 children over 12 months and third, conducting qualitative interviews with caregivers, community health workers, and health workers to understand post-discharge experiences and care barriers. Throughout the study, children are followed for up to 6 months after discharge through telephone and in-person visits to monitor outcomes such as mortality, hospital readmission, and quality of life changes. Data collection includes direct observations, surveys, and interviews to capture a comprehensive picture of childrens health trajectories and family experiences after leaving the hospital. The studys findings aim to improve risk prediction and post-discharge care in resource-limited settings.

Age: 5Years - 16YearsAll Genders
7 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times. Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends. During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.

Age: 18Years - 65YearsAll GendersPhase 2
12 locations
S

Actively Recruiting

This research aims to understand if infants and young children with sickle cell disease SCD develop adequate protection after receiving measles vaccines. It focuses on children aged between 6 months and 6 years who are eligible for measles vaccination as part of standard care. The study evaluates immune response specifically after the first and second doses of the measles vaccine without investigating long-term protection. Participants are divided into two groups one receiving their first measles vaccine MV1 and the other receiving their second measles vaccine MV2. Blood samples are collected before vaccination and then again at 4 and 8 weeks after vaccination to measure antibody response. The study tracks antibody development following each vaccine dose to assess vaccine immunogenicity in children with SCD. During the study, participants will have blood drawn at specified times and attend follow-up visits for sample collection and evaluations. Researchers will measure measles seroconversion rates at 4 and 8 weeks post-vaccination and analyze factors related to antibody responses. The study duration includes sample collection up to 8 weeks post-vaccination with additional analysis continuing up to 12 weeks. Families provide consent and participate in scheduled visits to support data collection.

Age: 6Months - 6YearsAll Genders
3 locations